Amendment to the Claims:

This listing of the claims will replace, without prejudice, all prior versions, and listings, of claims in the application.

1. (Canceled)

- 2. (Currently amended) A method for producing a mature dendritic cell, which comprises the step of
- (i) contacting a minus-strand RNA viral Sendai virus vector with a an immature dendritic cell or
- (ii) contacting a Sendai virus vector with a precursor cell thereof of a dendritic cell to cause the precursor cell to differentiate into an immature dendritic cell,

wherein said immature dendritic cell of (i) or (ii) undergoes maturation thereby producing a mature dendritic cell.

- 3. (Currently amended) The method of claim 1 or 2, wherein the contacting step involves contacting the minus-strand RNA viral Sendai virus vector with an immature dendritic cell.
- 4. (Currently amended) The method of claim 1-or 2, wherein the contacting step involves contacting the minus-strand RNA viral vector with a CD34⁺ cell the precursor cell is a CD34⁺ cell or CD11c⁺ cell.
- 5. (Currently amended) The method of claim 3 or 4, further comprising the step of wherein step (ii) comprises culturing the precursor cell in the presence of GM-CSF and IL-4 before or after the contact step contacting step.
- 6. (Currently amended) The method of claim 1 or 2, wherein the vector comprises a cytokine gene.

- 7. (Original) The method of claim 6, wherein the cytokine is interferon β .
- 8. (Canceled)
- 9. (Canceled)
- 10. (Currently amended) The method of claim 1 or 2, wherein the cell is a human cell.
- 11. (Currently amended) A <u>An isolated</u> vector-comprising <u>containing mature</u> <u>dendritic</u> cell produced by the method of <u>any one of claims 1 to 10 claim 2</u>.
 - 12. (Canceled)
- 13. (Original) A method for suppressing tumor growth, which comprises the step of delivering the dendritic cell of claim 11 to a tumor site.
- 14. (Currently amended) The method of claim 13, further comprising the step of contacting a tumor antigen with the dendritic cell and/or expressing the tumor a tumor antigen in the dendritic cell.
 - 15. (New) The method of claim 2, wherein the vector comprises a foreign gene.
- 16. (New) The mature dendritic cell of claim 11, wherein the vector comprises a foreign gene.
- 17. (New) The mature dendritic cell of claim 11, wherein the foreign gene encodes a cytokine or an antigenic peptide.

- 18. (New) The mature dendritic cell of claim 17, wherein the cytokine is interferon β .
- 19. (New) The mature dendritic cell of claim 11, wherein the cell is a human cell.
- 20. (New) The method of claim 1, which comprises the step of contacting a Sendai virus vector with a precursor cell of a dendritic cell and differentiating the cell into an immature dendritic cell, thereby the immature dendritic cell is spontaneously maturated.
- 21. (New) An isolated precursor of an immature dendritic cell comprising a Sendai virus vector.
- 22. (New) The cell of claim 21, wherein said cell is a CD11c⁺ precursor cell of an immature dendritic cell.
 - 23. (New) An isolated immature dendritic cell comprising a Sendai virus vector.
 - 24. (New) An isolated mature dendritic cell comprising a Sendai virus vector.